INTRODUCTION
============

The molecular signaling mechanisms by which glucocorticoid hormones regulate hippocampal neurogenesis are unknown. Stress increases circulating levels of endogenous glucocorticoids ([@bib37]; [@bib3]), which in turn decrease adult hippocampal neurogenesis ([@bib13]; [@bib4]; [@bib19]; [@bib52]). Importantly, impaired hippocampal neurogenesis in rodents has recently been shown to contribute to the development of depressive symptoms in response to stress ([@bib50]), suggesting that the glucocorticoid-induced reduction in neurogenesis may indeed contribute to the pathogenesis of major depression. Discovering the molecular signaling pathways by which glucocorticoids regulate hippocampal neurogenesis is, therefore, crucial to indentify potential targets for novel antidepressant treatments that counteract stress-induced neurobiological abnormalities.

Endogenous glucocorticoids (cortisol in humans and corticosterone (CORT) in rodents) act on two intracellular receptors: the mineralocorticoid receptor (MR), which has high affinity for endogenous glucocorticoids and is already activated by low, basal cortisol concentrations; and the glucocorticoid receptor (GR), which has low affinity for cortisol and is thus predominantly activated by high cortisol concentrations, as they occur upon stress and in depression ([@bib3]; [@bib37]; [@bib38]). We and others have demonstrated that stress and GR activation consistently decrease hippocampal neurogenesis *in vitro* and *in vivo* ([@bib4]; [@bib25]; [@bib16]; [@bib19]; [@bib31]; [@bib13]). In contrast, the role of the MR in neurogenesis is less clear, as some studies have reported a decrease in proliferation upon MR activation ([@bib55]; [@bib33]), while others have found an increase ([@bib15]; [@bib18]). Previous studies have investigated candidate genes involved in the stress- and glucocorticoid-induced reduction in neurogenesis ([@bib12]; [@bib48]; [@bib56]; [@bib30]). However, a complete analysis of the intricate signaling mechanisms that mediate the effects of glucocorticoids on the hippocampus is lacking.

To address this issue, we have first analyzed the effects of low (ie, MR-related) and high (GR-related) cortisol concentrations on an immortalized human hippocampal progenitor cell line, our established *in vitro* model of human neurogenesis in which we can determine the state of proliferation and neuronal differentiation by the addition and removal of growth factors ([@bib4]; [@bib58]). Using pharmacological agonists and antagonists for the MR and the GR, in combination with immunocytochemistry and whole genome expression analysis, we have dissected MR- and GR-mediated regulation of neurogenesis and astrogliogenesis. We have then conducted whole genome expression analysis of the rat hippocampus in animals subjected to prenatal stress, a well established animal model of depression in which glucocorticoid levels are elevated and hippocampal neurogenesis is decreased ([@bib27]; [@bib17]). Our study reveals novel molecular signaling pathways regulated consistently by cortisol in human hippocampal progenitor cells and by stress in the rat hippocampus.

MATERIALS AND METHODS
=====================

Cell Culture
------------

The immortalized, multipotent human fetal hippocampal progenitor cell line HPC03A/07 (provided by ReNeuron Ltd, UK) was used for all experiments ([@bib4]). HPC03A/07 cells proliferate in the presence of growth factors (EGF, FGF) and 4-hydroxytamoxifen (4-OHT), while differentiation is initiated upon growth factor and 4-OHT removal. Detailed information on this cell line and culture conditions can be found in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}.

Drugs
-----

All drugs and reagents were purchased from Sigma-Aldrich (St Louis, MO) unless otherwise stated. Growth factors EGF and bFGF were purchased from Peprotech (London, UK). Purmorphamine was from Millipore, UK. Aldosterone, dexamethasone, hydrocortisone, RU486 and spironolactone were dissolved in 100% ethanol. Purmorphamine was dissolved in 100% DMSO. Bromodeoxyuridine (BrdU) was dissolved in phosphate-buffered saline fresh before use.

Proliferation Assay
-------------------

Progenitor cell proliferation was assessed as previously described ([@bib4]) Briefly, HPC03A/07 cells were plated on 96-well plates (Nunclon, Roskilde, Denmark) at a density of 1.2 × 10^4^ cells per well and cultured for 72 h in the presence of growth factors and 4-OHT to maintain proliferation. The synthetic nucleotide 5′-BrdU, 10 μM) was added to the media 4 h before treatment cessation. Cells were fixed with 4% paraformaldehyde for 20 min at room-temperature.

Differentiation Assay
---------------------

Differentiation was assessed as previously described ([@bib4]). Briefly, cells were cultured in the presence of growth factors and 4-OHT for 3 days, and subsequently washed and cultured in media without growth factors and 4-OHT for further 7 days to allow differentiation. For these experiments, cells were treated during the initial proliferation phase and the subsequent differentiation phase, or only during the proliferation phase, or only during the differentiation phase. At the end of the total incubation time (10 days) cells were fixed as described above.

Immunocytochemistry
-------------------

Proliferation was assessed by immunolabelling for BrdU (rat anti-BrdU, Serotec, Oxford, UK). Differentiation into young and mature neurons was assessed by immunocytochemistry for Dcx (rabbit anti-Dcx, 1 : 1000, Abcam, Cambridge, UK) and microtubule-associated protein-2 (MAP2) (mouse anti-MAP-2\[HM\], 1 : 500, Abcam), respectively. Astrogliogenesis was evaluated by immunocytochemistry for S100 calcium-binding protein β (S100β) (rabbit anti-S100β, 1 : 500, DAKO, Glostrup, Denmark). Synaptic markers were detected by staining for synaptophysin (mouse anti-synaptophysin, 1 : 100, Assaydesigns) and Homer1 (rabbit anti-Homer1, 1 : 100, Synaptic Systems). Cells were also stained for the hippocampal granule-cell-marker, Prospero homeobox protein 1 (Prox1) (mouse anti-Prox1, 1 : 100, Abcam). Hoechst 33342 dye was used to label all cells. The number of Dcx-, MAP2-, S100β- and BrdU-positive cells over total Hoechst 33342-positive cells was determined to assess neurogenesis, astrogliogenesis, and progenitor proliferation (see [Supplementary Materials](#sup1){ref-type="supplementary-material"}).

GR Transactivation Assay
------------------------

To measure GR transactivation in HPC03A/07 cells upon cortisol treatment, nuclear protein extracts were obtained using a commercially available nuclear extraction kit (Active Motif, Rixensart, Belgium). GR binding to a consensus glucocorticoid response element DNA sequence was analyzed using the enzyme-linked immunosorbent assay-based TransAM GR method (Active Motif), according to the manufacturer\'s instructions.

Ethics Statement
----------------

All animal handling and experimental procedures were performed in accordance with the EC (EEC Council Directive 86/609 1987), the Italian legislation on animal experimentation (Decreto Legislativo 116/92), and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Prenatal Stress Study
---------------------

Nulliparous adult female (body weight 230--260 g) and male (400 g) Sprague-Dawley rats were pair-housed with a same-sex conspecific with food and water available *ad libitum* (21±1 °C, 60±10% relative humidity, reversed 12/12 h light/dark cycle). After 10 days, rats were mated for 24 h and individually housed immediately thereafter. Pregnant females were randomly assigned to delivery control (ctrl) and prenatal stress (PNS) conditions. PNS consisted of restraining pregnant dams in a transparent Plexiglas cylinder (7.5 cm diameter, 19 cm length) under bright light (6.500 l × ) for 45 min three times daily during the last week of gestation. PNS sessions were separated by 2--3 h intervals and conducted at varying periods of the day to reduce habituation. Control rats were left undisturbed. Male offspring from control and PNS groups were killed at postnatal day (PND) 62 for whole hippocampal dissection (*n*=7 for each group) and trunk blood collection (*n*=5 for each group).

CORT Analysis
-------------

Upon killing, trunk blood samples were collected individually in potassium EDTA tubes (1.6 mg EDTA/ml blood, Sarstedt, Germany). CORT was measured using a commercially available radioimmunoassay kit containing 125-Iodine labeled CORT (MP Biomedicals, CA). Assay sensitivity was 0.125 mg/dl. Vials were counted for 2 min in a gamma-scintillation counter (Packard Minaxi Gamma counter, Series 5000).

RNA Isolation, Microarray Processing, Quality Control
-----------------------------------------------------

RNA of human progenitor cells and rat hippocampal tissue was isolated using RNeasy mini kit (Qiagen, Crawley, UK) and subsequently DNase treated (Ambion, Warrington, UK). RNA was reverse transcribed using GeneAtlas 3′IVT Express Kit (Affymetrix, Santa Clara, CA).

Gene expression microarray assays were performed on three independent experiments using Human Genome U219 Array Strips (for the gene expression analyses in cells) and Rat Gene 1.1 T Array Strips (for the gene expression analyses in rat) on the Affymetrix GeneAtlas platform ([http//www.affymetrix.com/support/technicalmanual/expression_manual_affy](http://www.affymetrix.com/support/technicalmanual/expression_manual_affy)). Partek Genomics Suite 6.6 software was used for data visualization, statistical testing of affymetrix CEL files and quality control. Data quality was assessed using histograms of signal intensities, scatter plots, and hierarchical clustering of samples. All samples passed the criteria for hybridization controls, labeling controls and 3′/5′ Metrics. Robust MultiChip Average method was used for background correction and Quantiles normalization. Summarization was performed using a median polish algorithm ([@bib54]) (see also [Supplementary Materials](#sup1){ref-type="supplementary-material"}).

Pathway Analysis
----------------

Pathway analysis for progenitor cells and hippocampi of PNS rats was conducted with Pathway Studio Software 5.0 (Ariadne, Lausanne, Switzerland), using the standard Gene Set enrichment analysis, originally developed by the Broad Institute (<http://www.broad.mit.edu/gsea/>) ([@bib34]). This algorithm uses a correlation-weighted Kolmogorov--Smirnov statistic on all gene expression changes and computes pathway enrichment scores by considering gene set membership information, gene list ranking and gene--gene dependencies that reflect real biology. We used *P*\<0.005 as enrichment *P*-value cutoff for pathway analysis in human hippocampal progenitor cells, and *P*\<0.05 as enrichment *P*-value cutoff for pathway analysis in PNS rat hippocampi.

Quantitative Real-time PCR
--------------------------

RNA from human cells and rat hippocampal tissue was reverse transcribed with Superscript III (Invitrogen) before quantitative Real-Time PCR (qPCR) using the SYBR Green method ([Supplementary Materials](#sup1){ref-type="supplementary-material"}).

Statistical Analysis
--------------------

All statistical analyses for immunocytochemistry and qPCR were performed with GraphPad Prism 4.03 (GraphPad, La Jolla) on independent biological replicates (indicated as '*n*\'). One-way ANOVA with Newman-Keuls *post hoc* test was used for multiple comparisons among the treatment groups. Student\'s *t*-test was used to compare means of two independent treatment groups. *P*-values\<0.05 were considered significant. Data are presented as mean±s.e.m.

ANOVA was used in the gene expression microarray to assess the effects of cortisol treatment on progenitor cells and the effects of PNS in rats. To investigate the effects of cortisol on progenitor cells, a three linear contrast was performed using Partek Genomic Suite 6.6 (cortisol 100 nℳ *vs* vehicle; cortisol 100 μM *vs* vehicle; cortisol 100 μM *vs* cortisol 100 nℳ) with a maximum filter of *P*\<0.05 and a minimum absolute fold-change cutoff of 1.2. Genes that passed these criteria were used to build up the Venn diagram ([Supplementary Figure 4a](#sup1){ref-type="supplementary-material"}, [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). For both, cortisol-treated cells and adult PNS rats, the cluster diagrams were built up using genes fulfilling the criteria of *P*\<0.01 and 1.2 minimum absolute fold-change ([Supplementary Tables 4 and 5](#sup1){ref-type="supplementary-material"}; [Supplementary Figures 5 and 6](#sup1){ref-type="supplementary-material"}).

RESULTS
=======

Differential MR- and GR-dependent Effects of Cortisol on Progenitor Cell Proliferation
--------------------------------------------------------------------------------------

We first analyzed the effects of a wide range of cortisol concentrations (1 nM--100 μM) on proliferation of human hippocampal progenitor cells after 3 days of treatment, using BrdU incorporation and immunocytochemistry ([Figure 1a](#fig1){ref-type="fig"}).

Cortisol treatment showed dose-dependent, bimodal effects on proliferation (One-way ANOVA, *P*\<0.0001, *F*~1,7~=6.76, *n*=4). Specifically, low concentrations (1 nM--100 nM) increased proliferation (by 16% at 100 nℳ, *P*=0.002, *n*=4; [Figure 1b](#fig1){ref-type="fig"}, third column), whereas high concentrations (1 μℳ-100 μℳ) decreased proliferation (by -17% at 100 μℳ, *P*=0.002, *n*=4; [Figure 1b](#fig1){ref-type="fig"}, last column). In order to investigate whether MR and GR are involved in these effects, we co-treated cells with cortisol (again 1 nℳ--100 μℳ) and with the MR antagonist, spironolactone (1 μℳ), or the GR antagonist, RU486 (50 nℳ). Spironolactone, but not RU486, blocked the increase in proliferation upon treatment with low cortisol concentrations (1 nM--100 nM), indicating that this effect is mediated by the MR ([Figure 1c](#fig1){ref-type="fig"}). Conversely, RU486, but not spironolactone, blocked the decrease in proliferation upon treatment with high cortisol concentrations (1 *μ*ℳ--100 μℳ) ([Figure 1d](#fig1){ref-type="fig"}), indicating that this effect is mediated by the GR.

To confirm these findings, we also examined whether MR- and GR-agonists would model the differential effects of low- and high-cortisol concentrations on proliferation. Indeed, the MR-agonist, aldosterone (1 nℳ--1 μℳ), increased proliferation (One-way ANOVA, *P*=0.02, *F*~1,5~=3.27, *n*=3; [Figure 1e](#fig1){ref-type="fig"}), modeling the effects of low cortisol concentrations. Moreover, the GR-agonist, dexamethasone (10 nℳ--5 μℳ), decreased proliferation (One-way ANOVA, *P*\<0.0001, *F*~1,5~=7.66, *n*=3; [Figure 1f](#fig1){ref-type="fig"}), modeling the effects of high cortisol concentrations and confirming our previous data on decreased proliferation upon dexamethasone treatment (1 μℳ) in the same model ([@bib4]).

To further confirm that the higher cortisol concentrations used in our study do not fully saturate the GR, we examined GR transactivation upon cortisol treatment over a wider range of concentrations (100 nℳ--2 mℳ). In line with our data on progenitor cell proliferation (described above), low doses of cortisol (100 nℳ) did not significantly induce GR binding to the DNA, while GR transactivation was dose-dependently increased following higher cortisol concentrations (10 μM--2 mℳ). Moreover, the concentration of 100 μℳ cortisol did not saturate the GR, as transactivation could be further increased by concentrations of up to 2 mℳ ([Figure 1g](#fig1){ref-type="fig"}). Concentrations of cortisol higher than 2 mℳ induced cell death.

MR- and GR-dependent Effects of Cortisol on Differentiation into Neurons
------------------------------------------------------------------------

To examine the effects of cortisol on neuronal differentiation, cells were treated with two cortisol concentrations selected for predominant MR activation (100 nℳ) or GR activation (100 μM), as described above. Cells were cultured for 3 days under proliferation conditions and subsequently allowed to differentiate by removal of growth factors and 4-OHT for subsequent 7 days. Immunocytochemistry for MAP2 and Dcx was used to visualize mature neurons and young neuroblasts, respectively ([Figure 2a](#fig2){ref-type="fig"}, top panels; [Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}).

When cells were treated only during the proliferation phase (3 days) but not during the subsequent differentiation phase (7 days), both cortisol concentrations decreased neuronal differentiation. Specifically, the low concentration (100 nℳ) decreased MAP2-positive neurons by −24% (*P*=0.005, *n*=3; [Figure 2b](#fig2){ref-type="fig"}). As expected, this effect was counteracted by the MR antagonist, spironolactone (1 μM), and mimicked by the MR-agonist, aldosterone (1 μℳ) (−21%, *P*=0.01, *n*=3; [Figure 2b](#fig2){ref-type="fig"}). Similar effects were observed when we counted the number of Dcx-positive neuroblasts ([Supplementary Results](#sup1){ref-type="supplementary-material"}, [Supplementary Figure 1b](#sup1){ref-type="supplementary-material"}). The high cortisol concentration (100 μℳ) also decreased MAP2-positive neurons by −22% (*P*=0.002, *n*=3; [Figure 2c](#fig2){ref-type="fig"}). This effect was abolished by RU486 (50 nM), and mimicked by dexamethasone (1 μM) (−27%, *P*=0.001, *n*=3; [Figure 2c](#fig2){ref-type="fig"}). Again, similar effects were observed when we counted the number of Dcx-positive neuroblasts ([Supplementary Results](#sup1){ref-type="supplementary-material"}, [Supplementary Figure 1c](#sup1){ref-type="supplementary-material"}). These data demonstrate that MR activation and GR activation both decrease neuronal differentiation.

When cells were treated continuously during both, the proliferation [and]{.ul} the differentiation phase, we observed similar effects on MAP2- and Dcx-positive cells ([Supplementary Results](#sup1){ref-type="supplementary-material"}, [Supplementary Figure 2a-d](#sup1){ref-type="supplementary-material"}). In contrast, treatment only during the differentiation phase, but not during the preceding proliferation phase, did not exert any significant effects ([Figure 2d and e](#fig2){ref-type="fig"}, [Supplementary Figure 1d and e](#sup1){ref-type="supplementary-material"}), supporting the notion that MR- and GR-activation during the proliferation phase is necessary and sufficient to reduce neuronal differentiation.

All experiments above were conducted by allowing cells to differentiate for 7 days. In order to elucidate whether these newborn neurons continue to further develop into hippocampal granule neurons that express synaptic markers, we analyzed the expression of synaptic markers and hippocampal granule-cell markers after longer periods of differentiation (5 weeks), when most cells have already fully differentiated into MAP2-positive neurons. Indeed, differentiated HPC03A/07 neurons express the synaptic markers, synaptophysin and homer1, as well as the hippocampal granule-cell-marker, Prox1 ([@bib24]) ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

MR- and GR-dependent Effects of Cortisol on Differentiation into Astrocytes
---------------------------------------------------------------------------

Next, we wanted to test whether the MR- and GR-mediated decrease in neuronal differentiation, described above, is associated with a cortisol-induced shift of progenitor cell fate from neuronal- to astrocyte-differentiation. We thus treated cells with cortisol and analyzed the number of S100β-positive astrocytes ([Figure 2a](#fig2){ref-type="fig"}, bottom panels). Treatment with the low cortisol concentration (100 nM) and aldosterone (1 μM) only during the proliferation phase increased the number of S100β-positive astrocytes (by 23%, *P*=0.003, *n*=3; and by 20%, *P*=0.004, respectively; [Figure 2f](#fig2){ref-type="fig"}). Both effects were abolished by spironolactone (1 μM) ([Figure 2f](#fig2){ref-type="fig"}). In contrast, the high cortisol concentration (100 μM) and dexamethasone (1 μM) did not change the number of S100*β*-positive astrocytes ([Figure 2g](#fig2){ref-type="fig"}), demonstrating for the first time that MR activation, but not GR activation, induces astrocyte differentiation of human hippocampal progenitor cells. However, when interpreting our data it needs to be considered that the high cortisol concentration *also* activates the MR ([@bib14]). Notably, this high concentration induced a small increase in S100*β*-positive astrocytes in the presence of RU486 ([Figure 2g](#fig2){ref-type="fig"}, second column). Therefore, the lack of effect suggests that predominant GR activation may inhibit the MR-mediated increase in astrogliogenesis (as also suggested by our pathway analysis, see below), resulting in the net effect of no changes.

When cells were treated continuously during proliferation and differentiation, similar effects on S100β-positive astrocytes were observed ([Supplementary Result**s**](#sup1){ref-type="supplementary-material"}, [Supplementary Figure 2e and f](#sup1){ref-type="supplementary-material"}). Finally, and similar to the effects on neuronal differentiation, treatment only during the differentiation phase, but not during the preceding proliferation phase, did not exert any significant effects ([Figure 2h and i](#fig2){ref-type="fig"}), supporting the notion that MR activation during the proliferation phase is necessary and sufficient to induce astrogliogenesis.

Taken together, our results indicate that MR activation increases hippocampal progenitor cell proliferation while concomitantly shifting cell fate from neuronal- toward astrocyte differentiation. In contrast, GR activation decreases proliferation and neuronal differentiation and counteracts the MR-induced increase in astrogliogenesis.

Regulation of Molecular Signaling Pathways by Low and High Cortisol Concentrations
----------------------------------------------------------------------------------

Having discovered such profound effects of MR- and GR-mediated cortisol action on hippocampal neurogenesis, we wanted to establish the molecular signaling pathways implicated in these effects. We focused specifically on the signaling mechanisms during the proliferation phase, as treatment during this phase was necessary and sufficient to reduce neurogenesis and to increase astrogliogenesis, as described above. We analyzed gene expression changes after 12 hours of cortisol treatment, because our initial real-time PCR analysis had shown the most significant effects of cortisol on two selected glucocorticoid-regulated genes (FKBP5, FOXO1) specifically at this time point ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). In this Results section we present the results of the pathway analysis, as this analysis best captures the complex signaling mechanisms induced by low- and high-concentrations of cortisol (presented in [Table 1](#tbl1){ref-type="table"}). The complete gene expression analysis is presented in [Supplementary Figure 5a and 6](#sup1){ref-type="supplementary-material"}, [Supplementary Table 3 and 4](#sup1){ref-type="supplementary-material"} and in the [Supplementary Results](#sup1){ref-type="supplementary-material"}.

The low cortisol concentration (100 nℳ) regulated 36 pathways (*P*\<0.005). Of particular relevance is the activation of Notch- and Hairy/Enhancer of Split (Hes)-signaling, which is crucially involved in changing neuronal- to astroglial cell fate ([@bib23]). Activation of this pathway may thus potentially be involved in the above described MR-mediated shift from neurogenesis to astrogliogenesis upon treatment with low cortisol concentrations in our experiments.

The high cortisol concentration (100 μM) regulated five pathways (*P*\<0.005), among which TGFβ-SMAD2/3-signaling was downregulated and FOXO3A signaling was activated ([Table 1](#tbl1){ref-type="table"}). Both pathways have been implicated in neurogenesis, depression, and glucocorticoid action ([@bib46]; [@bib20]; [@bib45]; [@bib35]), and their regulation is thus consistent with decreased progenitor proliferation in our experiments. However, opposite to the effect of the low concentration, the high cortisol concentration *decreased* Notch/Hes-signaling (at a lower significance level: *P*=0.04). This could possibly be explained by high cortisol concentrations predominantly activating the GR, thereby inhibiting the MR-mediated increase in these signaling pathways present with low concentrations.

Finally, both low and high cortisol concentrations significantly regulated seven pathways. Inhibition of Hedgehog signaling is thereby particularly relevant, because activation of this pathway promotes neuronal differentiation ([@bib1]; [@bib10]), which, as described above, is decreased upon treatment with low and high cortisol concentrations in our experiments.

Stimulation of Hedgehog Signaling Counteracts Cortisol Effects on Neurogenesis
------------------------------------------------------------------------------

In order to test the hypothesis that inhibition of Hedgehog signaling is indeed part of the mechanism by which cortisol decreases neurogenesis, we co-treated cells with cortisol and with the smoothened (SMO)-agonist, purmorphamine, which activates Hedgehog signaling ([@bib47]). As expected, purmorphamine (1 nℳ--1 μℳ) increased neuronal differentiation into MAP2-positive neurons (One-way ANOVA, *P*=0.02, *F*~1,4~=3.88, *n*=3; [Figure 3a](#fig3){ref-type="fig"}) and into Dcx-positive neuroblasts (One-way ANOVA, *P*=0.13, *F*~1,4~=2, *n*=3; *t*-test: veh *vs* Purmorphamine 1 μℳ, *P*=0.03, *n*=3; [Figure 3b](#fig3){ref-type="fig"}). Importantly, co-treatment with the two lowest concentrations of purmorphamine, which do not exert an effect on neuronal differentiation by themselves (1 nℳ and 10 nℳ, see [Figure 3a and b](#fig3){ref-type="fig"}), counteracted the decrease in MAP2- and Dcx-positive neurons upon treatment with 100 nM ([Figure 3c and d](#fig3){ref-type="fig"}) and with 100 μℳ of cortisol ([Figure 3e and f](#fig3){ref-type="fig"}). These data support the notion that inhibition of Hedgehog signaling by cortisol significantly contributes to the decrease in neuronal differentiation.

Regulation of Molecular Signaling Pathways in Prenatally Stressed Rats
----------------------------------------------------------------------

In order to compare our *in vitro* findings in human cells with an *in vivo* model of stress-induced biological and behavioral abnormalities, we conducted gene expression microarray and pathway analysis in the hippocampus of prenatally stressed (PNS) rats, a well established animal model of depression in which hippocampal neurogenesis is decreased ([@bib27]; [@bib39]). Consistent with the literature, adult PNS rats (PND 62) exhibited significantly increased blood concentrations of CORT (control: 226±66 ng/ml, *n*=5; PNS: 437±82 ng/ml, *n*=5; *P*=0.03). Again, here we present the results of the pathway analysis (see [Table 2](#tbl2){ref-type="table"}), while the complete gene expression analysis is presented in [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}, [Supplementary Table 5](#sup1){ref-type="supplementary-material"} and in the [Supplementary Results](#sup1){ref-type="supplementary-material"}. Importantly, we found that, among the eight pathways regulated in the hippocampus of adult PNS rats (*P*\<0.05), TGFβ-SMAD2/3- and Hedgehog signaling were both inhibited, which is the same effect that we observed in human hippocampal progenitor cells treated with high, stress-relevant concentrations of cortisol (described above).

qPCR Validation of Affymetrix Findings
--------------------------------------

To confirm the importance of Hedgehog signaling for cortisol and stress effects, both *in vitro* and *in vivo*, we analyzed expression of three key targets of Hedgehog signaling by qPCR: the transcription factor, Gli, the Hedgehog pathway activator, SMO, and the Hedgehog-interacting protein, HHIP1. Both, in cortisol-treated hippocampal progenitor cells and in the hippocampus of adult PNS rats, we found a significant reduction of Gli (CORT 100 nM: 0.66±0.08 fold, *P*=0.02, *n*=3, CORT 100 μM: 0.71±0.07 fold, *P*=0.02, *n*=3; PNS: 0.64±0.05 fold, *P*=0.006, *n*=5) and SMO (CORT 100 nM: 0.76±0.04 fold, *P*=0.03, *n*=3, CORT 100 μM: 0.55±0.1 fold, *P*=0.04, *n*=3; PNS: 0.82±0.03, *P*=0.002, *n*=5), and an increase in HHIP1, which *inhibits* Hedgehog signaling (CORT 100 nM: 1.9±0.24 fold, *P*=0.03, *n*=3, CORT 100 μM: 2.4±0.36 fold, *P*=0.02, *n*=3; PNS: 1.24±0.09 fold, *P*=0.04, *n*=5). Together, these data confirm our finding that Hedgehog signaling is decreased upon cortisol treatment in human hippocampal progenitor cells and by PNS in the adult rat hippocampus.

In addition, we further validated 10 of the most significantly regulated genes with an absolute fold-change of \>1.3 fold for each cortisol concentration (100 nM and 100 μM) and for PNS rats ([Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}). We found a high correlation of the fold-changes detected by affymetrix and by qPCR (cortisol-treated progenitor cells: Pearson\'s correlation: *r*=0.92, *r*^2^=0.84, *P*\<0.0001; [Supplementary Figure 5b](#sup1){ref-type="supplementary-material"}; Hippocampi of adult PNS rats: Pearson\'s correlation: *r*=0.995, *r*^2^=0.99, *P*\<0.001; [Supplementary Figure 5c](#sup1){ref-type="supplementary-material"}).

DISCUSSION
==========

Here, we identify for the first time the molecular signaling pathways regulated by cortisol in human hippocampal progenitor cells and by PNS in the adult rat hippocampus. Firstly, we demonstrate that low and high cortisol concentrations exert differential MR- and GR-dependent effects on human hippocampal neurogenesis. We found that low cortisol concentrations, by predominantly activating the MR, increase progenitor cell proliferation and shift neuronal development towards astrocyte development, while high concentrations of cortisol, by predominantly activating the GR, reduce *both* proliferation and neuronal differentiation, and inhibit the MR-induced increase in astrogliogenesis. At the molecular level, low cortisol concentrations enhance Notch/Hes-signaling, high cortisol concentrations inhibit TGFβ-SMAD2/3-signaling, and both concentrations inhibit Hedgehog signaling. We also demonstrate that this inhibition of Hedgehog signaling is critically involved in the cortisol-induced decrease in neurogenesis. Secondly, and in line with the effects of high cortisol concentrations on human hippocampal progenitor cells, TGFβ-SMAD2/3- and Hedgehog signaling are also downregulated in the hippocampus of adult prenatally stressed rats with elevated glucocorticoid levels. We are confident that these novel findings shed light on important molecular mechanisms underlying stress-related disorders, such as major depression.

The differential and common effects of MR- and GR-activation on proliferation and neuronal differentiation have never been shown in a human model, but have been suggested by previous studies in rodents. For example, GR activation by high glucocorticoid levels, as they occur upon stress and in depression, consistently decreases hippocampal cell proliferation and neuronal differentiation *in vivo* ([@bib19]; [@bib13]; [@bib31]) and *in vitro* ([@bib25]; [@bib57]). Importantly, GR^+/\ −^ mice with a 50% gene dose reduction in the whole body, and mice with a forebrain-specific deletion of the GR, show stress hypersensitivity and reduced hippocampal neurogenesis ([@bib42]; [@bib26]; [@bib7]), possibly caused by impaired hypothalamus--pituitary--adrenal (HPA) axis feedback inhibition and subsequent hypercortisolemia, affecting the hippocampus. Accordingly, mice overexpressing the GR are stress-resistant ([@bib42]). Interestingly, GR deletion in the entire nervous system causes increased CORT levels but does not elicit decreased hippocampal neurogenesis ([@bib53]; [@bib18]). In contrast to the GR, MR activation by aldosterone increases hippocampal progenitor proliferation in adrenalectomized rats ([@bib15]), while MR knockout decreases proliferation ([@bib18]), and the MR antagonist, spironolactone, increases neuronal differentiation ([@bib11]). These animal studies, together with our human cellular data, therefore, support the notion that MR- and GR-activation indeed exert opposite effects on progenitor proliferation, while activation of both receptors decreases neuronal differentiation.

Interestingly, we identified several relevant molecular signaling mechanisms involved in the differential MR- and GR-mediated effects of cortisol on hippocampal neurogenesis and astrogliogenesis. The low cortisol concentration (100 nM) activates Notch-/Hes-signaling, which has been shown by previous studies to increase progenitor proliferation and glia differentiation ([@bib21]; [@bib23]), an effect that we indeed observe in our experiments. In contrast, the high cortisol concentration *downregulates* Notch/Hes-signaling, thereby potentially inhibiting MR-mediated effects on proliferation and astrogliogenesis. Moreover, the high cortisol concentration inhibits TGFβ-SMAD2/3-signaling, which has previously been shown to be decreased upon GR activation ([@bib32]; [@bib5]) and in depressed patients ([@bib35]). Furthermore, increased TGFβ signaling promotes neurogenesis *in vitro* and *in vivo* ([@bib5]; [@bib20]; [@bib45]), suggesting that the cortisol-induced *inhibition* of this pathway may potentially contribute to the GR-dependent decrease in neurogenesis in our cellular model.

Finally, both low and high concentrations of cortisol inhibit Hedgehog signaling. Hedgehog signaling promotes neuronal differentiation ([@bib1]; [@bib10]; [@bib23]) and inhibition of this pathway is therefore in line with decreased neurogenesis upon treatment with both low and high cortisol concentrations in our study. Indeed, we demonstrate that stimulating Hedgehog signaling with the pharmacological compound, purmorphamine, counteracts the cortisol-induced decrease in neurogenesis, supporting the notion that inhibition of this pathway may be significantly involved in the effects of cortisol on neurogenesis.

Importantly, in our experiments TGFβ-SMAD2/3- and Hedgehog signaling are also downregulated in the hippocampus of adult rats with increased blood glucocorticoid levels as a result of PNS, an established animal model of depression ([@bib17]). This is the same effect that we observed in our cellular model upon treatment with high (stress-relevant) concentrations of cortisol, again indicating that common signaling pathways may be particularly relevant for stress- and glucocorticoid effects on the hippocampus, both in human cells and in rodent tissue. Indeed we found that three key targets of Hedgehog signaling---the transcription factor, Gli, the Hedgehog receptor, SMO, and the Hedgehog inhibitor, HHIP1---are regulated exactly in the same way by cortisol *in vitro* and by PNS *in vivo*. It is noteworthy, however, that despite these striking similarities, we have also found pathways and genes that were regulated differently by high cortisol concentrations *in vitro* and by stress *in vivo*, most likely due to the fact that the majority of cells in the hippocampus are neurons and glia cells, while progenitor cells only comprise a very small portion of the hippocampus. Accordingly, previous gene expression studies upon cortisol treatment in other cell types or tissues, such as fibroblasts, pre-adipocytes or fetal whole brain tissue, have found some similarities in gene expression when compared with our study, probably because cortisol was used as a common stimulus; but they also found many differences, likely due to tissue-specific effects of glucocorticoids ([@bib49]; [@bib9]; [@bib43]). In particular, cortisol-induced changes in Hedgehog signaling were not detected by these studies on other cell types, supporting the notion that the regulation of Hedgehog signaling may indeed be most relevant for the hippocampus and for hippocampal progenitor cells.

Are our findings relevant to the understanding of depression pathogenesis? Post-mortem studies have confirmed that patients with major depression---a condition often characterized by elevated glucocorticoids---show reduced hippocampal neurogenesis, while antidepressants reverse or prevent this effect ([@bib6]; [@bib29]). Moreover, we have shown that antidepressants reduce glucocorticoid actions *in vitro* using human hippocampal progenitor cells ([@bib4]), as well as *in vivo* using electroencephalography ([@bib36]) and neuroendocrine tests (Pariante, 2003). Therefore, the prevailing model suggests that excessive MR- and GR-stimulation by hypercortisolemia reduces neurogenesis in the hippocampus of depressed patients, which can be rescued by effective antidepressant treatment. It is, however, important to emphasize that the 'neurogenesis hypothesis\' of depression is not universally accepted. For example, some studies have questioned a potential functional role for hippocampal neurogenesis, because relatively few new neurons are being added to the adult brain ([@bib40]). Furthermore, one human post-mortem brain study did not find any changes in hippocampal cell proliferation in depressed patients, although the study sample was heterogeneous and comprised depressed and antidepressant-treated patients ([@bib41]). Moreover, rodent studies have suggested that reduced neurogenesis *per se* may indeed not contribute to the development of depression, while being critical for the effects of antidepressants ([@bib44]; [@bib51]). However, more recent studies have demonstrated that neurogenesis significantly contributes to the regulation of the HPA axis and depressive behavior in rodents ([@bib50]; [@bib52]), suggesting that reduced neurogenesis may impair hippocampal inhibitory control over the HPA axis during stress, subsequently causing sustained hypercortisolemia and depressive symptoms ([@bib2]).

A possible limitation of our *in vitro* model is that the immortalized human fetal hippocampal progenitor cells, while being invaluable for our understanding of the molecular mechanisms in the human hippocampus, may differ from the situation in a adult organism *in vivo*. Moreover, the cortisol concentrations used in our *in vitro* experiments are likely higher than the so far unknown physiological concentrations in the brain of stressed or depressed humans. It is important to emphasize that the differences between the *in vivo* cortisol and *in vitro* CORT concentrations in our study may be explained by the high abundance of albumin in the cell culture media and the reportedly high expression of 11β-hydroxysteroid dehydrogenase 2 and multidrug-resistant p-glycoprotein in fetal tissue and stem cells ([@bib8]; [@bib22], [@bib28]). These factors likely diminish cortisol bioavailability in our progenitor cell system, thereby making potentially higher concentrations necessary to specifically activate corticosteroid receptors. Indeed, our dose--response study of GR activation shows that the GR is not saturated at the high cortisol concentration (100 μM). A further clear limitation of the *in vitro* model employed in this study is that no data is yet available on electrophysiological properties of differentiated HPC03A/07 cells. It will thus be an important line of future investigation to examine whether HPC03A/07 cells develop electrophysiological properties of functionally mature neurons, in order to fully characterize the potential impact of this cellular model for functional neuronal network properties and human neurogenesis *in vitro*.

In conclusion, our data shed light on the effects of cortisol on human hippocampal neurogenesis and astrogliogenesis, and identify novel molecular signaling pathways involved in the effects of glucocorticoids and stress on the hippocampus. Targeting these pathways may provide future treatment strategies to counteract cortisol-induced impairments in hippocampal plasticity in depressed patients.
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![Differential effects of mineralocorticoid receptor (MR)- and glucocorticoid receptor (GR)-activation on human hippocampal progenitor cell proliferation. 5′-bromodeoxyuridine (BrdU, 10 μℳ) incorporation and immunocytochemistry was used to assess proliferation of HPC03A/07 cells (a). Cortisol exerts bimodal, dose-dependent effects on proliferation (b). Spironolactone (1 μℳ) blocks the increase in cell proliferation upon treatment with low concentrations of cortisol (c). RU486 (50 nM) blocks the decrease in cell proliferation upon treatment with high concentrations of cortisol (100 μℳ) (d). The MR-agonist, aldosterone (1 nM--1 μℳ), increases cell proliferation (e), while the GR-agonist, dexamethasone (10 nℳ--5 μℳ), decreases cell proliferation (f). GR transactivation is dose-dependently increased by cortisol concentrations (10 μℳ--1 mℳ) (g). Three to four independent experiments were conducted on independent cultures (indicated as *n*). In proliferation experiments, four wells were analyzed per treatment condition in each experiment and three random, non-overlapping pictures were analyzed for each well. All data are mean±s.e.m. \**P*\<0.05, \*\**P*\<0.01; \*\*\**P*\<0.001 compared with the vehicle-treated control condition.](npp2012253f1){#fig1}

![Low and high concentrations of cortisol exert differential MR- and GR-dependent effects on neurogenesis and astrogliogenesis. Immunocytochemistry for microtubule-associated protein 2 (MAP2) and S100 calcium-binding protein β (S100ß) (a). If treated only during the proliferation phase, the low cortisol concentration (100 nM) and aldosterone (1 μℳ) decrease the number of MAP2-positive neurons. Both effects are counteracted by spironolactone (1 μℳ) (b). The high cortisol concentration (100 μℳ) and dexamethasone (1 μℳ) also decrease the number of MAP2-positive neurons. These effects are both counteracted by RU486 (50 nℳ) (c). No effects on the number of MAP2-positive neurons are observed when cells are treated only during the differentiation phase (d, e). the low cortisol concentration (100 nM) and aldosterone (1 μM) increase the number of S100β-positive astrocytes. Both effects are counteracted by spironolactone (1 μM) (f). The high cortisol concentration (100 μM) and dexamethasone (1 μℳ) do not significantly alter the number of S100β-positive astrocytes (g). No effects are observed on the number of S100β-positive astrocytes when cells are treated only during the differentiation phase (h, i). Three independent experiments were conducted on independent cultures (*n*=3). Four wells were analyzed per treatment condition in each experiment and three random, non-overlapping pictures were analyzed for each well. All data are mean±s.e.m. \**P*\<0.05, \*\**P*\<0.01, compared with the vehicle-treated control condition.](npp2012253f2){#fig2}

![Effects of purmorphamine on neurogenesis. Purmorphamine increases neuronal differentiation into microtubule-associated protein 2 (MAP2)-positive neurons (a) and into doublecortin (Dcx)-positive neuroblasts (b). The decrease in MAP2- and Dcx-positive cells upon treatment with the low cortisol concentration (100 nℳ) is counteracted by purmorphamine (10 nℳ) (c, d). The decrease in MAP2- and Dcx-positive cells upon treatment with the high cortisol concentration (100 μM) is also counteracted by purmorphamine (10 nM) (e, f). Three independent experiments were conducted on independent cultures (*n*=3). Four wells were analyzed per treatment condition in each experiment and three random, non-overlapping pictures were analyzed for each well. All data are mean±s.e.m. \**P*\<0.05, compared with the vehicle-treated control condition or as indicated.](npp2012253f3){#fig3}

###### Pathways regulated by cortisol in human hippocampal progenitor cells

  **Pathways regulated by cortisol 100 nM**                                                               
  ------------------------------------------------------ ------------ ----------------------------------- -----------------------------------
  Notch pathway                                               \+      0.00003                             
  VEGFR → ATF/CREB/ELK-SRF signaling                          −       0.00004                             
  ICAM1 → AP-1/CREB/ELK-SRF signaling                         \+      0.00005                             
  EGFR/ERBB2 → TP53 signaling                                 \+      0.00006                             
  EGFR/ERBB2 -\> HIF1A signaling                              \+      0.0001                              
  ProstaglandinFR → ATF1/ELK-SRF/CREB signaling               \+      0.0001                              
  ThrombinR → AP-1/CREB/ELK-SRF/SP1 signaling                 \+      0.0001                              
  EphrinR → actin signaling                                   \+      0.0001                              
  DopamineR2 → AP-1/CREB/ELK-SRF signaling                    \+      0.0001                              
  EndothelinRa → AP-1/CREB signaling                          \+      0.0001                              
  VasopressinR1 → CREB/ELK-SRF/AP-1/EGR signaling             \+      0.0002                              
  EGFR/ERBB2 → CTNNB signaling                                −       0.0002                              
  Axon Guidance                                               \+      0.0002                              
  EndothelinRb → AP-1/CREB/ELK-SRF signaling                  \+      0.0002                              
  EGFR → SMAD1 signaling                                      \+      0.0003                              
  EGFR/ERBB3 → MEF/MYOD/NFATC/MYOG signaling                  \+      0.0003                              
  Focal adhesion regulation                                   \+      0.0005                              
  EGFR → CTNND signaling                                      −       0.0006                              
  ProstaglandinIR → ATF1/ELK-SRF/CREB signaling               \+      0.0007                              
  IL13R → STAT6 signaling                                     \+      0.0008                              
  ERBB2/3 → EP300/ETS/ETV/SP1 signaling                       \+      0.0009                              
  VasopressinR2 → CREB/ELK-SRF/AP-1/EGR signaling             \+      0.001                               
  PTAFR → AP-1/ATF1/CREB/ERK-SRF signaling                    \+      0.001                               
  Mast cell activation                                        \+      0.001                               
  B-cell activation                                           \+      0.001                               
  KIT → MITF signaling                                        \+      0.002                               
  Hairy, Hairy/E(SPL) signaling                               \+      0.002                               
  FGFR → RUNX2 signaling                                      \+      0.002                               
  EDG3/5 → AP-1/ELK-SRF signaling                             \+      0.002                               
  IL4R → ELK-SRF/HMGY signaling                               \+      0.002                               
  T-cell receptor → ATF/CREB signaling                        \+      0.002                               
  CannabinoidR → AP-1/EGR signalingNK cell activation         \+      0.002                               
  NeurotensinR → ELK-SRF/AP-1/EGR signaling                   \+      0.003                               
  MAP3K signaling                                             \+      0.003                               
  VasopressinR1 → MEF/MYOD/NFATC/MYOG signaling               \+      0.003                               
  Actin cytoskeleton regulation                               \+      0.003                               
                                                                                                          
  **Pathways regulated by cortisol 100 μM**                                                               
  **Pathway name**                                        **Change**  **P-value**                         
  T-cell activation                                          *+*      0.0001                              
  TGFβ receptor → SMAD2/3 signaling                          *−*      0.001                               
  GF signaling                                               *+*      0.002                               
  GFR → FOXO3A signaling                                     *+*      0.002                               
  Endocytosis                                                *+*      0.004                               
                                                                                                          
  **Pathways regulated by cortisol 100 nM and 100 μM**                                                    
  **Pathway name**                                        **Change**  **P-value Corticosterone 100 nM**   **P-value Corticosterone 100 μM**
  Hedgehog pathway                                           *−*      0.005                               0.0002
  GFR → NCOR2 signaling                                      *+*      0.0001                              0.00008
  GFR → AP-1/CREB/CREBBP/ELK-SRF/MYC signaling               *+*      0.0005                              0.0006
  Adherens junction regulation                               *+*      0.003                               0.0003
  Guanylate cyclase pathway                                  *+*      0.004                               0.0004
  Apoptosis regulation                                       *+*      0.003                               0.003
  Gonadotrope cell activation                                *+*      0.005                               0.00003

###### Pathways Regulated by Prenatal Stress in the Rat Hippocampus

  **Pathway name**                        **Change**  ***P*-value**
  -------------------------------------- ------------ ---------------
  NF-kB signaling                             −       0.018
  TGFβ Receptor → SMAD2/3-signaling           −       0.026
  Insulin Action                              \+      0.034
  Glycogen metabolism                         \+      0.037
  Fatty acid oxidation                        \+      0.046
  Hedgehog pathway                            −       0.047
  Leptin receptor → ELK--SRF signaling        \+      0.049
  ROS metabolism                              −       0.049
